The company is presenting two distinct posters on June 15 that bridge the gap between patient-reported burdens and objective clinical metrics. The first, led by Ashley Slagle, examines the severity and rapid onset of withdrawal symptoms through a qualitative study of 15 adults, highlighting the significant hurdles patients face when attempting to reduce or cease cannabis use.

The second presentation details results from the Phase 2 CAN-002 clinical trial. Data shows that the investigational drug PP-01 achieved a statistically significant 43% reduction in irritability—a key symptom of withdrawal—compared to a placebo (P = 0.01) during the second through fifth days of the study. Ginger Constantine, CEO of PleoPharma, noted that these findings reinforce the drug's potential as a first-in-class treatment. PP-01 is designed to address neurotransmitter dysregulation in the mesolimbic reward pathway and is currently advancing toward further clinical development.